Comparison of continuous subcutaneous hydromorphone hydrochloride and morphine hydrochloride injection on skin disorders incidence: a retrospective study

被引：0

作者：

Tanaka, Rei ^{[1
,2
,3
]}

Hashizume, Takahiro ^{[1
]}

Hisanaga, Tadashi ^{[1
]}

Masuda, Shinya ^{[1
,4
]}

Sato, Junya ^{[2
]}

Ishikawa, Hiroshi ^{[1
]}

Tanaka, Hironori ^{[1
,3
,4
]}

Saitoh, Akiyoshi ^{[3
]}

Sato, Tetsumi ^{[5
]}

Kamoshida, Takeshi ^{[1
]}

Sato, Tetsu ^{[1
]}

Shino, Michihiro ^{[1
]}

机构：

[1] Shizuoka Canc Ctr, Dept Pharm, Shizuoka, Japan

[2] Shonan Univ Med Sci, Fac Pharmaceut Sci, Yokohama, Kanagawa, Japan

[3] Tokyo Univ Sci, Fac Pharmaceut Sci, Chiba, Japan

[4] Wakakusa Dispensing Pharm, Shizuoka, Japan

[5] Shizuoka Canc Ctr, Div Palliat Med, Shizuoka, Japan

来源：

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES | 2024年 / 10卷 / 01期

关键词：

Hydromorphone; Morphine; Opioid; Subcutaneous injection; Skin disorders; PALLIATIVE CARE; CANCER PAIN; MANAGEMENT;

D O I：

10.1186/s40780-024-00401-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BackgroundContinuous subcutaneous administration of injectable opioids is simple and effective; however, skin disorders may occur when high opioid dosages are used. Therefore, we investigated opioid injection drugs with a low risk of skin disorders.MethodsA retrospective study was conducted using the electronic medical records of patients prescribed 1% hydromorphone hydrochloride or 4% morphine hydrochloride with instructions for continuous subcutaneous administration at Shizuoka Cancer Center from January 2017 to December 2021. The primary endpoint was skin disorders incidence, and the two groups were compared using Cox proportional hazards model analyses and Fisher's exact test at 5% significance level. Patient background factors expected to influence skin disorders were also investigated, and multivariate logistic analysis of skin disorders incidence was performed.ResultsThe incidence of skin disorders in the hydromorphone hydrochloride and morphine hydrochloride groups were 3.7% (1/27 patients) and 28.1% (9/32 patients), respectively, showing a significant difference in two statistical analyses between the two groups (Cox proportional hazards model analyses HR: 0.09, 95% CI: 0.01-0.70, P = 0.022. Fisher's exact test OR: 0.10, 95% CI: 0.01-0.84, P = 0.016). In the multivariate analysis, the administration of hydromorphone hydrochloride (OR: 0.04, 95% CI: 0.003-0.48, P = 0.012) was also found to have a significant negative correlation with the occurrence of skin disorders. On the contrary, administration period >= 28 days (OR: 18.16, 95% CI: 2.22-148.60, P = 0.007) was a factor with a significant positive correlation.ConclusionsSubcutaneous 1% hydromorphone hydrochloride administration had a lower risk of skin disorders than 4% morphine hydrochloride injection. Moreover, prolonging the administration period increased the risk of developing skin disorders. This suggests that a 1% hydromorphone hydrochloride Injection is a good clinical decision for patients who are likely to have a longer administration period and require a higher dosage of injectable opioids.Trial registrationRetrospectively registered.

引用

页数：7

共 27 条

[1]

Adams F, 1989, J Pain Symptom Manage, V4, P31, DOI 10.1016/0885-3924(89)90061-4

[2]

[Anonymous], The package insert of NARUVEIN Injection 2mg 10mg in Japan

[3]

[Anonymous], The package insert of OXIFAST Injection 50mg 10mg in Japan

[4]

[Anonymous], The package insert of Fentanyl Injection. 0.1mg 0.25mg 0.5mg in Japan

[5]